TransEnterix, Inc.
Aug 3, 2017
PDF

TransEnterix Announces First Senhance U.S. Innovation Center at Florida Hospital Orlando

Innovation Center will serve as clinical training and procedural development site

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has installed a Senhance Surgical Robot at the Institute for Surgical Advancement at Florida Hospital Orlando.

The Senhance Robot is placed under a collaboration agreement with Florida Hospital ISA. Nicholson Center Orlando will be used as a facility to perform pre-clinical training and procedural development in cooperation with surgical staff from Florida Hospital. Additionally, surgeons from around the world are participating in the robotic pre-clinical activities at the innovation center.

"The selection of a U.S. innovation center is a critical milestone in the global expansion of Senhance," said Todd M. Pope, President and CEO at TransEnterix. "We are pleased to partner with a leading institution such as Florida Hospital Orlando and the clinicians at the Institute for Surgical Advancement. Together, we will continue to usher in an expansion in the use of robotics to advance minimally invasive surgery."

"We have created a center for the interdisciplinary development of new surgical approaches utilizing the latest technology," said Dr. Steve Eubanks, Surgeon and Executive Director for the Institute for Surgical Advancement. "Our team is excited to be the first U.S. center to explore the clinical and training pathway for this new surgical robotic platform, and to share these programs with surgeons from across the globe."

About Florida Hospital Institute for Surgical Advancement

The Institute for Surgical Advancement was developed to facilitate the success of physicians who have the capabilities and desires to innovate academically and through procedural and instrumentation development. Through our various resources, we facilitate and assess the needs of our physicians to help develop advancements for patient care and innovate new surgical approaches. Combining physician experience with expertise in engineering improves the early phases of design and encourages the flow of ideas. We have various resources for this process, including the brainstorming room, our prototype lab, and Florida Hospital Nicholson Center, a world leader in surgical training. For more information, visit https://www.floridahospitalisa.com.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark, and is currently under FDA review for clearance in the United States. For more information, visit the TransEnterix website at www.transenterix.com.

About Florida Hospital Nicholson Center

For over a decade, Florida Hospital Nicholson Center has trained more than 70,000 physicians from around the globe on leading-edge clinical and surgical techniques. Utilizing state-of-the-art surgical suites, and labs, plus advanced medical simulation robotics and learning centers, medical professionals can acquire and advance their skills in a highly collaborative surgical learning environment. For more information please visit NicholsonCenter.com.

Forward Looking Statements

This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the partnering between TransEnterix, Florida Hospital Orlando and the clinicians at the Institute for Surgical Advancement will continue to usher in an expansion in the use of robotics to advance miniminally invasive surgery . For a discussion of the risks and uncertainties associated with TransEnterix' s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 7, 2017 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For TransEnterix, Inc.
Investor Contact:
Mark Klausner, +1-443-213-0501
invest@transenterix.com
or
Media Contact:
(For EU) Conrad Harrington, +44 (0)20 3178 8914
(For US) Hannah Dunning, +1-415-618-8750
TransEnterix-SVC@sardverb.com

Source: TransEnterix, Inc.

News Provided by Acquire Media